3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
28
Leukemia
27
Anemia, Refractory, with Excess of Blasts
26
Leukemia, Myeloid, Acute
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia, Myelomonocytic, Chronic
19
Leukemia, Myeloid, Chronic-Phase
17
Leukemia, Myeloid, Accelerated Phase
17
Myeloproliferative Disorders
16
Lymphoma
16
Lymphoma, Non-Hodgkin
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Congenital Abnormalities
13
Burkitt Lymphoma
13
Blast Crisis
13
Hodgkin Disease
12
Primary Myelofibrosis
11
Multiple Myeloma
11
Lymphoma, Mantle-Cell
11
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Follicular
11
Myelodysplastic-Myeloproliferative Diseases
10
Lymphoma, Large B-Cell, Diffuse
10
Anemia, Refractory
10
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
9
Neoplasms, Plasma Cell
8
Dendritic Cell Sarcoma, Interdigitating
8
Recurrence
6
Neutropenia
6
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
Classical hematology
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled